Previous 10 | Next 10 |
-- ORR of 70 .0 % Observed in Patients with NHL Treated with Higher Doses of ALX148 with Median Duration of Response Not Yet Reached -- Significant Improvement in Clinical Response Demonstrated with Increased ALX148 Exposure BURL...
-- Due to the registration potential of two planned Phase 2 head and neck cancer studies , FDA has requested completion of a standard ongoing non-clinical safety study -- Initiation of planned Phase 2 studies is allowed ...
BURLINGAME, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President an...
The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow
ALX Oncology (ALXO): Q3 GAAP net loss of $10.8MNon-GAAP net loss of $9.1MCash and cash equivalents of $259.5MPress Release For further details see: ALX Oncology reports Q3 results
BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended ...
The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology (ALXO) Investor Presentation - Slideshow
-- ORR of 64 % Observed in Patients with > 2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- ORR of 75% and One Complete Response Observed in Patients with 1L Head and Neck Cancer -- ALX Onco...
BURLINGAME, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that both ALX148 clinical and preclinical re...
BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President an...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...